2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Aldose Reductase
  5. Aldose Reductase Inhibitor

Aldose Reductase Inhibitor

Aldose Reductase Inhibitors (38):

Cat. No. Product Name Effect Purity
  • HY-N0102
    Isoliquiritigenin
    		Inhibitor 98.02%
    Isoliquiritigenin is an anti-tumor flavonoid from the root of Glycyrrhiza uralensis Fisch., which inhibits aldose reductase with an IC50 of 320 nM. Isoliquiritigenin is a potent inhibitor of influenza virus replication with an EC50 of 24.7 μM.
  • HY-66009
    Epalrestat
    		Inhibitor 99.72%
    Epalrestat is an aldose reductase inhibitor for the treatment of diabetic neuropathy.
  • HY-105185
    Fidarestat
    		Inhibitor 99.35%
    Fidarestat (SNK 860) is an inhibitor of aldose reductase, with IC50s of 26 nM, 33 μM, and 1.8 μM for aldose reductase, AKR1B10 and V301L AKR1B10, respectively; Fidarestat (SNK 860) has the potential to treat diabetic disease.
  • HY-106697
    Ponalrestat
    		Inhibitor 99.71%
    Ponalrestat (ICI 128436) is an orally active, selective and noncompetitive aldose reductase (AKR1B1; ALR) inhibitor. Ponalrestat selectively inhibits ALR2 (Ki=7.7 nM) over ALR1 (Ki=60 μM). Ponalrestat inhibits the conversion of glucose to sorbitol.
  • HY-16500
    Tolrestat
    		Inhibitor 99.37%
    Tolrestat is a potent, orally active aldose reductase inhibitor with IC50 of 35 nM.
  • HY-151947
    ALR2-IN-3
    		Inhibitor
    ALR2-IN-2 is a potent inhibitor of aldose reductase (ALR2), with IC50s of 22 nM and 116 nM for rat ALR2 and ALR1, respectively. ALR2-IN-2 can be used for the research of diabetic complications.
  • HY-106877
    Minalrestat
    		Inhibitor
    Minalrestat (ARI-509) is a potent and orally active aldose reductase inhibitor. Minalrestat can be used in the research of diabetes.
  • HY-151946
    ALR2-IN-2
    		Inhibitor
    ALR2-IN-2 is a potent inhibitor of aldose reductase (ALR2), with IC50s of 27 nM and 228 nM for rat ALR2 and ALR1, respectively. ALR2-IN-2 can be used for the research of diabetic complications.
  • HY-N0310
    Soyasaponin Bb
    		Inhibitor 99.13%
    soyasaponin Bb is a soyasaponin isolated from Phaseolus vulgaris, acting as an aldose reductase differential inhibitor (ARDI).
  • HY-16255
    Imirestat
    		Inhibitor 99.86%
    Imirestat (AL 1576) is an aldose reductase inhibitor, used for the treatment of diabetes.
  • HY-15314
    Ranirestat
    		Inhibitor 98.32%
    Ranirestat (AS-3201) potent and orally active aldose reductase (AR) inhibitor with IC50s of 11 nM and 15 nM for rat lens AR and recombinant human AR, respectively, and a Ki of 0.38 nM for recombinant human AR. Ranirestat has the potential for diabetic sensorimotor polyneuropathy treatment. Ranirestat also has a neuroprotective effect on diabetic retinas.
  • HY-106198
    Lidorestat
    		Inhibitor 99.50%
    Lidorestat (IDD-676) is a potent, selective and orally active aldose reductase inhibitor with an IC50 of 5 nM. Lidorestat can be used for chronic diabetes complications. Lidorestat also improves nerve conduction and reduces cataract formation.
  • HY-B1202
    Alrestatin
    		Inhibitor 99.80%
    Alrestatin is an inhibitor of aldose reductase, an enzyme involved in the pathogenesis of complications of diabetes mellitus, including diabetic neuropathy.
  • HY-N0033
    Poliumoside
    		Inhibitor 99.80%
    Poliumoside, a caffeoylated phenylpropanoid glycoside, is isolated from Brandisia hancei stems and leaves. Poliumoside is an advanced glycation end product (AGE) formation and rat lens aldose reductase (RLAR) inhibitor, with IC50s of 19.69 and 8.47 μM, respectively. Poliumoside also has antiinflammatory and antioxidant activity.
  • HY-129586
    AT-007
    		Inhibitor 99.37%
    AT-007 is an orally active central nervous system (CNS) penetrant Aldose Reductase inhibitor for treatment of Galactosemia with an IC50 value of 100 pM. AT-007 reduces toxic galactitol levels and prevents disease complications in GALT deficiency rats.
  • HY-18967
    Caficrestat
    		Inhibitor 99.88%
    Caficrestat (Aldose reductase-IN-1) is a inhibitor of aldose reductase with IC50 of 28.9 pM.
  • HY-50289
    Sorbinil
    		Inhibitor 99.85%
    Sorbinil, is an Aldose reductase inhibitor (ARI). Sorbinil plays therapeutic role in treating diabetes and diabetic complications, decreases AR activity and inhibits polyol pathway, it to be found comparatively safer than other ARIs for human use.
  • HY-19687
    Zopolrestat
    		Inhibitor 99.94%
    Zopolrestat (CP73850) is a potent, orally active aldose reductase (AR) inhibitor with an IC50 of 3.1 nM. Zopolrestat is used for the research of diabetic complications.
  • HY-13633
    Exisulind
    		Inhibitor 98.03%
    Exisulind is an inactive metabolite of the nonsteroidal, anti-inflammatory agent sulindac. Exisulind inhibits aldose reductase with an IC50 of 367 nM in vitro and may contribute to the beneficial pharmacological effects of sulindac on type 2 diabetic complications.
  • HY-16433
    Risarestat
    		Inhibitor 98.09%
    Risarestat (CT-112), an aldose reductase inhibitor, is developed for the treatment of diabetic complications.